Oscar Health Inc

OSCR remains in a clear Stage 2 advancing uptrend with both long‐ and medium‐term structures rising, but the recent blow‐off top and overbought extension above the 9/21 EMAs warrant patience. Medium‐term bias is bullish under Stage 2, yet short‐term execution is deferred until shallow pullbacks into the rising 9/21 EMA support zone, where a favorable entry asymmetry may develop.

• ↑Revenue surged to $4.6B in Q1 (+53% YoY); members hit 3.2M (+56% YoY).
• ↑SG&A expense ratio reached a historic low of 15.2% after AI integration.
• ↓MLR rose to 91.1%, highlighting higher claims and risk costs.